Life sciences investor Catalio Capital Management has been on a fundraising tear since it spun out of private equity firm Camden Partners Holdings slightly more than two years ago. If dealmaking continues to founder in a sputtering economy, Catalio will be well positioned to take advantage of declining valuations.